NUVL
Nuvalent, Inc. [NUVL] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
NUVL Stock Summary
Top 10 Correlated ETFs
NUVL
Top 10 Correlated Stocks
NUVL
In the News
Nuvalent to Present Preliminary Data from ALKOVE-1 Phase 1/2 Clinical Trial of NVL-655 at 35th AACR-NCI-EORTC Symposium
Company plans to host a conference call on October 13, 2023 CAMBRIDGE, Mass. , Sept. 18, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced it will present preliminary dose-escalation data from its ongoing ALKOVE-1 Phase 1/2 clinical trial of NVL-655 at the 35th AACR-NCI-EORTC (ANE) Symposium taking place October 11-15, 2023, in Boston, Massachusetts.
Nuvalent to Participate in Upcoming September Investor Conferences
CAMBRIDGE, Mass. , Aug. 31, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.
Deerfield Management Company, L.P.
Deerfield Management Company, L.P. (Series C), a renowned investment firm, recently made a significant addition to its portfolio.
Nuvalent to Participate in Upcoming August Investor Conferences
CAMBRIDGE, Mass. , Aug. 1, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.
Recent Price Trend in Nuvalent, Inc. (NUVL) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Nuvalent, Inc. (NUVL) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Nuvalent, Inc. (NUVL) Is a Great Choice for 'Trend' Investors, Here's Why
Nuvalent, Inc. (NUVL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Nuvalent to Present ALKOVE-1 Trial in Progress Poster for NVL-655 at the European Lung Cancer Congress (ELCC 2023)
CAMBRIDGE, Mass. , March 23, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming poster presentation for the ongoing Phase 1/2 ALKOVE-1 study of its ALK-selective inhibitor, NVL-655.
Nuvalent to Present New Preclinical Data on ALK-Selective Inhibitor NVL-655 at AACR Annual Meeting 2023
CAMBRIDGE, Mass. , March 14, 2023 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced an upcoming preclinical data poster presentation supporting the ongoing clinical development of its ALK-selective inhibitor, NVL-655.
Nuvalent to Present at the 41st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. , Jan. 4, 2023 /PRNewswire/ -- Nuvalent, Inc., (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.
MDA Breakout Stocks Week 1 - January 2023: High-Frequency Gainers To Give You An Edge
Two new Breakout Stocks for Week 1 with better than 10% short-term upside potential and two Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. The streak of weekly picks gaining over 10% in less than a week of trading days has reached 235 out of 293 trading weeks (80.4%) not counting multiple gainers.
NUVL Financial details
NUVL Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | |
| Net income per share | -0.73 | -0.64 | -2.13 | -1.48 | |
| Operating cash flow per share | -0.6 | -0.65 | -1.84 | -1.31 | |
| Free cash flow per share | -0.6 | -0.65 | -1.84 | -1.31 | |
| Cash per share | 0.19 | 0.45 | 13.23 | 9.51 | |
| Book value per share | -1.07 | -1.37 | 13.08 | 9.32 | |
| Tangible book value per share | -1.07 | -1.37 | 13.08 | 9.32 | |
| Share holders equity per share | -1.07 | -1.37 | 13.08 | 9.32 | |
| Interest debt per share | 0.13 | 0.1 | 0 | 0.09 | |
| Market cap | 303.22M | 428.7M | 414.76M | 1.48B | |
| Enterprise value | 302.37M | 420.6M | 346.24M | 1.24B | |
| P/E ratio | -25.68 | -29.45 | -8.95 | -20.17 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | |
| POCF ratio | -31.46 | -28.68 | -10.37 | -22.77 | |
| PFCF ratio | -31.46 | -28.68 | -10.37 | -22.77 | |
| P/B Ratio | -17.57 | -13.69 | 1.46 | 3.19 | |
| PTB ratio | -17.57 | -13.69 | 1.46 | 3.19 | |
| EV to sales | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -29.19 | -24.88 | -7.56 | -14.37 | |
| EV to operating cash flow | -31.37 | -28.14 | -8.66 | -19.04 | |
| EV to free cash flow | -31.37 | -28.14 | -8.66 | -19.04 | |
| Earnings yield | -0.04 | -0.03 | -0.11 | -0.05 | |
| Free cash flow yield | -0.03 | -0.03 | -0.1 | -0.04 | |
| Debt to equity | -0.13 | -0.07 | 0 | 0 | |
| Debt to assets | 0.66 | 0.21 | 0 | 0 | |
| Net debt to EBITDA | 0.08 | 0.48 | 1.5 | 2.81 | |
| Current ratio | 0.76 | 2.43 | 33.07 | 24.54 | |
| Interest coverage | 0 | 0 | 0 | -20.24 | |
| Income quality | 0.82 | 1.03 | 0.86 | 0.79 | |
| Dividend Yield | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | |
| Graham number | 4.19 | 4.43 | 25.03 | 17.6 | |
| ROIC | 0.69 | 0.58 | -0.16 | -0.17 | |
| Return on tangible assets | -3.56 | -1.37 | -0.16 | -0.15 | |
| Graham Net | -1.09 | -1.38 | 12.82 | 9.11 | |
| Working capital | -1.04M | 6.27M | 281.84M | 458.51M | |
| Tangible asset value | -17.26M | -31.32M | 285.04M | 462.98M | |
| Net current asset value | -17.26M | -31.32M | 281.84M | 458.51M | |
| Invested capital | -0.13 | -0.07 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | |
| Average payables | 0 | 987.5K | 2.07M | 5.04M | |
| Average inventory | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | |
| ROE | 0.68 | 0.46 | -0.16 | -0.16 | |
| Capex per share | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-06-30 for Q2
| Metric | History | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.38 | -0.39 | -0.37 | -0.36 | -0.51 | |
| Operating cash flow per share | -0.32 | -0.38 | -0.33 | -0.43 | -0.39 | |
| Free cash flow per share | -0.32 | -0.38 | -0.33 | -0.43 | -0.39 | |
| Cash per share | 5.32 | 4.96 | 8.81 | 7.94 | 7.58 | |
| Book value per share | 5.24 | 4.89 | 8.64 | 7.83 | 7.41 | |
| Tangible book value per share | 5.24 | 4.89 | 8.64 | 7.83 | 7.41 | |
| Share holders equity per share | 5.24 | 4.89 | 8.64 | 7.83 | 7.41 | |
| Interest debt per share | -0.01 | -0.01 | 0.06 | -0.09 | 0.09 | |
| Market cap | 655.21M | 941.1M | 1.6B | 1.48B | 2.4B | |
| Enterprise value | 579.29M | 864.79M | 1.35B | 1.39B | 2.33B | |
| P/E ratio | -9 | -12.35 | -20.19 | -18.33 | -20.61 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -42.34 | -51.78 | -89.81 | -60.6 | -108.34 | |
| PFCF ratio | -42.34 | -51.78 | -89.81 | -60.6 | -108.34 | |
| P/B Ratio | 2.59 | 3.98 | 3.45 | 3.33 | 5.69 | |
| PTB ratio | 2.59 | 3.98 | 3.45 | 3.33 | 5.69 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -30.92 | -42.42 | -46.24 | -45.99 | -68.32 | |
| EV to operating cash flow | -37.43 | -47.58 | -76.21 | -56.91 | -105.14 | |
| EV to free cash flow | -37.43 | -47.58 | -76.21 | -56.91 | -105.14 | |
| Earnings yield | -0.03 | -0.02 | -0.01 | -0.01 | -0.01 | |
| Free cash flow yield | -0.02 | -0.02 | -0.01 | -0.02 | -0.01 | |
| Debt to equity | 0 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | 4.05 | 3.74 | 8.25 | 2.98 | 2.08 | |
| Current ratio | 25.79 | 18.9 | 24.54 | 26.81 | 21.01 | |
| Interest coverage | 70.16 | 30.34 | -9.23 | 6.02 | -6.85 | |
| Income quality | 0.84 | 0.92 | 0.68 | 0.97 | 0.76 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 6.66 | 6.58 | 8.46 | 7.92 | 9.23 | |
| ROIC | -0.07 | -0.08 | -0.05 | -0.05 | -0.08 | |
| Return on tangible assets | -0.07 | -0.08 | -0.04 | -0.04 | -0.07 | |
| Graham Net | 5.11 | 4.69 | 8.44 | 7.64 | 7.22 | |
| Working capital | 248.79M | 232.27M | 458.51M | 439.27M | 416.2M | |
| Tangible asset value | 252.99M | 236.58M | 462.98M | 443.97M | 421.15M | |
| Net current asset value | 248.79M | 232.27M | 458.51M | 439.27M | 416.2M | |
| Invested capital | 0 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 4.14M | 4.32M | 5.91M | 6.81M | 7.28M | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.07 | -0.08 | -0.04 | -0.05 | -0.07 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
NUVL Frequently Asked Questions
What is Nuvalent, Inc. stock symbol ?
Nuvalent, Inc. is a US stock , located in Cambridge of Ma and trading under the symbol NUVL
What is Nuvalent, Inc. stock quote today ?
Nuvalent, Inc. stock price is $45.95 today.
Is Nuvalent, Inc. stock public?
Yes, Nuvalent, Inc. is a publicly traded company.
Company Profile
- Volume Average 351.61K
- Market Capitalization 2.49B
- Employee 78
- CEO Dr. James R. Porter Ph.D.
- Headquarters Cambridge,MA,US
- IPO Date 2021-07-29
-
Website
https://www.nuvalent.com 
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
